Skip to content
+1 (888) 687-4334 | sales@mountainside-medical.com
New users? Get 5% off on your first purchase.
Free US shipping over $100
New users? Get 5% off on your first purchase.
Free US shipping over $100
Login

Added to your cart:

Cart subtotal

View cart (2) Checkout
Immune Globulin Injection Syringes Injectable Medications Prefilled Syringes, Autoinjectors, Pre-filled Drug Delivery Systems Prescription Medications & Prescription Drugs Immune System Disorder Products Immune System Health Products Medical Supplies Unit Dose Medications

Filters

Availability
Price
$
-
$
$0 $1695
Vendor
Collection
Tags

Intravenous Immune Globulin Injections for Immunoglobulin Therapy

Intravenous Immune Globulin (IVIG) – Immunoglobulin Therapy Explained

Intravenous Immune Globulin (IVIG) is a treatment where a purified solution of antibodies (immunoglobulins) is infused directly into a patient’s vein. In simpler terms, it’s an “antibody transfusion”. This therapy provides a person with a large pool of antibodies collected from the plasma of thousands of healthy donors. By delivering these antibodies intravenously, IVIG can boost or modulate the immune system, and it’s used to treat a variety of conditions. The term “immunoglobulin therapy” refers to this use of antibody preparations (like IVIG) as medications to help patients who either lack sufficient antibodies or have immune systems that need regulation.

What Exactly Is in IVIG?

IVIG is made from human plasma, the liquid part of blood. Plasma from many donors is pooled and processed to extract Immunoglobulin G (IgG), which is the main type of antibody in our blood. IgG is important for fighting infections – it recognizes bacteria, viruses, and other invaders and helps neutralize them or mark them for destruction. Each IVIG dose contains a broad spectrum of IgG antibodies reflecting immunity present in the donor population. In fact, each batch of IVIG contains antibodies from thousands of donors (often 1,000 to 15,000 people or more), ensuring a wide variety of antibodies. The manufacturing process includes steps to remove or inactivate viruses and bacteria, making the product as safe as possible. The final IVIG solution is usually a 5-10% concentration of IgG in water (with some stabilizing proteins or sugars), and it looks like a clear or pale yellow fluid.

Because IVIG comes from human donors, it provides polyclonal antibodies – meaning many different antibodies against many antigens. It’s not a targeted, single-antibody treatment, but rather a collection of antibodies that together can cover a range of common infections. Some IVIG products contain trace amounts of IgA and IgM (other antibody types), but IgG is the primary component and the workhorse of the therapy.

IVIG is a form of immunoglobulin therapy where concentrated antibodies from donor plasma are given through a vein. It serves two main purposes: to replace antibodies in people who don’t have enough, and to regulate the immune system in people whose immune responses are causing harm. This therapy has become a cornerstone for treating immunodeficiencies, allowing patients to lead much healthier lives than they would without antibodies. It’s also an important weapon against certain autoimmune and inflammatory conditions, often achieving results when other treatments fail. When you hear “immunoglobulin therapy,” IVIG is the prototypical example – a versatile, antibody-based treatment delivering passive immunity or immune modulation via intravenous injection.

People Also Searched For

Intravenous Immune Globulin Injections for Immunoglobulin Therapy by Grifols Therapeutics Intravenous Immune Globulin Injections for Immunoglobulin Therapy to doctor-only Intravenous Immune Globulin Injections for Immunoglobulin Therapy to Human Immune Globulin Immune Globulin Injection Syringes Injectable Medications Prefilled Syringes, Autoinjectors, Pre-filled Drug Delivery Systems Prescription Medications & Prescription Drugs Immune System Disorder Products Immune System Health Products

Intravenous Immune Globulin (IVIG) – Immunoglobulin Therapy Explained

Intravenous Immune Globulin (IVIG) is a treatment where a purified solution of antibodies (immunoglobulins) is infused directly into a patient’s vein. In simpler terms, it’s an “antibody transfusion”. This therapy provides a person with a large pool of antibodies collected from the plasma of thousands of healthy donors. By delivering these antibodies intravenously, IVIG can boost or modulate the immune system, and it’s used to treat a variety of conditions. The term “immunoglobulin therapy” refers to this use of antibody preparations (like IVIG) as medications to help patients who either lack sufficient antibodies or have immune systems that need regulation.

What Exactly Is in IVIG?

IVIG is made from human plasma, the liquid part of blood. Plasma from many donors is pooled and processed to extract Immunoglobulin G (IgG), which is the main type of antibody in our blood. IgG is important for fighting infections – it recognizes bacteria, viruses, and other invaders and helps neutralize them or mark them for destruction. Each IVIG dose contains a broad spectrum of IgG antibodies reflecting immunity present in the donor population. In fact, each batch of IVIG contains antibodies from thousands of donors (often 1,000 to 15,000 people or more), ensuring a wide variety of antibodies. The manufacturing process includes steps to remove or inactivate viruses and bacteria, making the product as safe as possible. The final IVIG solution is usually a 5-10% concentration of IgG in water (with some stabilizing proteins or sugars), and it looks like a clear or pale yellow fluid.

Because IVIG comes from human donors, it provides polyclonal antibodies – meaning many different antibodies against many antigens. It’s not a targeted, single-antibody treatment, but rather a collection of antibodies that together can cover a range of common infections. Some IVIG products contain trace amounts of IgA and IgM (other antibody types), but IgG is the primary component and the workhorse of the therapy.

IVIG is a form of immunoglobulin therapy where concentrated antibodies from donor plasma are given through a vein. It serves two main purposes: to replace antibodies in people who don’t have enough, and to regulate the immune system in people whose immune responses are causing harm. This therapy has become a cornerstone for treating immunodeficiencies, allowing patients to lead much healthier lives than they would without antibodies. It’s also an important weapon against certain autoimmune and inflammatory conditions, often achieving results when other treatments fail. When you hear “immunoglobulin therapy,” IVIG is the prototypical example – a versatile, antibody-based treatment delivering passive immunity or immune modulation via intravenous injection.

How Is IVIG Administered?
Who Needs IVIG and Why?
Why Intravenous?

How Is IVIG Administered?

IVIG is given by intravenous infusion, typically in a hospital, infusion center, or sometimes at home by a trained nurse. A small needle is placed into a vein (often in the arm), and the IVIG solution is dripped in slowly over the course of several hours. A typical infusion might last anywhere from 2 to 6 hours, depending on the dose and how well the patient tolerates it. Because it’s a potent foreign protein, it’s infused slowly at first to watch for any reactions. Medical personnel monitor the patient’s vital signs and comfort during the infusion.

The frequency of IVIG infusions depends on the condition being treated:

  • For immunodeficiency syndromes where the body doesn’t make enough antibodies, IVIG is often given on a regular schedule (e.g., every 3 to 4 weeks). The goal is to maintain a protective level of antibodies in the bloodstream at all times. Each dose “wears off” gradually as the antibodies get used up or normal metabolism clears them, so repeat infusions are needed to keep immunity up. Some patients will receive these infusions indefinitely (essentially as a lifelong replacement therapy for their missing immune function).
  • For autoimmune or inflammatory conditions (like Guillain-Barré syndrome, immune thrombocytopenia, or Kawasaki disease), IVIG might be given as a short-term treatment – for example, daily infusions for 2-5 days in a row – to tamp down the immune attack. In other chronic autoimmune diseases, it could be given at intervals (like monthly) to help maintain remission. The exact regimen can vary widely based on the disease and how the person responds.
  • For acute exposures (like being exposed to hepatitis or rabies), an IVIG (or an IM injection of immunoglobulin) is given as a one-time dose soon after exposure to provide immediate antibodies.

IVIG administration requires planning: patients are often pre-medicated with something like acetaminophen or an antihistamine to minimize side effects (for example, headaches or infusion reactions). They are also advised to stay well-hydrated. The infusion is increased in rate gradually if the patient is tolerating it well. If a patient cannot tolerate IV infusions (due to reactions or poor vein access), there is an alternative method called subcutaneous immunoglobulin (SCIG) where the same product is infused under the skin in smaller, more frequent doses. However, SCIG is usually for maintenance therapy in immunodeficiencies – when the question says “intravenous immune globulin,” it specifically refers to the IV route, which is used for higher doses and acute treatments.

Who Needs IVIG and Why?

IVIG is used as a therapy for a range of immune-related conditions, broadly falling into two categories:

  1. Replacing missing or deficient antibodies (Immunoglobulin Replacement Therapy).
  2. Modulating an overactive immune system (Immunomodulation).

1. Replacement Therapy for Immune Deficiencies: Some people’s bodies do not produce enough antibodies on their own, leaving them vulnerable to infections. These conditions can be genetic (primary immunodeficiencies like CVID, X-linked agammaglobulinemia, etc.) or acquired (for example, certain cancers like CLL or treatments that suppress antibody production). For these patients, IVIG is literally a lifesaver. It supplies the antibodies they lack, helping to prevent recurrent infections. After starting IVIG, these patients typically see a dramatic drop in serious infections, hospitalizations, and antibiotic use. It doesn’t “cure” the immunodeficiency, but it effectively takes over the role of the missing immune components. Think of it as giving the immune system some hired mercenaries to patrol the body since the native soldiers are few or none. This use of IVIG is long-term and preventive; it’s not treating an immediate infection, but rather preventing infections from taking hold in the first place by ensuring pathogens are met with antibodies as soon as they invade.

2. Immunomodulation for Autoimmune/Inflammatory Diseases: In high doses, IVIG can calm an overactive immune system. It’s somewhat paradoxical – we’re adding antibodies, yet it can turn down immune attacks. The mechanisms are complex, but IVIG can interfere with the immune system’s communication and suppress harmful immune cells or autoantibodies. Conditions treated this way include:

  • Immune Thrombocytopenic Purpura (ITP): Here, a person’s immune system is destroying their platelets. IVIG infusions often quickly raise platelet counts by saturating the cells that would otherwise gobble up platelets. It’s used if someone has very low platelets and is bleeding or at risk of bleeding.
  • Guillain-Barré Syndrome: An acute autoimmune neuropathy where the immune system attacks peripheral nerves, leading to weakness and paralysis. IVIG (given over 5 days) is a first-line treatment that can shorten the course and intensity of the illness, likely by neutralizing or blocking the immune factors attacking the nerves.
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A chronic cousin of Guillain-Barré – patients may receive periodic IVIG (e.g., monthly) to maintain muscle strength and nerve function.
  • Myasthenia Gravis: In severe cases or crises, IVIG can be used to reduce the attack on acetylcholine receptors in muscles.
  • Kawasaki Disease: A pediatric inflammatory condition affecting blood vessels; a one-time high-dose IVIG (usually 2 g/kg) given over 8-12 hours, ideally within the first 10 days of illness, dramatically reduces the risk of coronary artery aneurysms and helps calm the inflammation.
  • Other autoimmune conditions: While not first-line, IVIG is sometimes used in refractory cases of systemic lupus, dermatomyositis (a muscle inflammation), antiphospholipid syndrome (to prevent recurrent clotting in pregnancy, for example), and even neurological disorders like multiple sclerosis or stiff-person syndrome. It’s also been explored in Alzheimer’s disease and other conditions, though evidence varies.
  • Transplant medicine: IVIG combined with medications is used in some transplant settings to desensitize patients (reduce antibodies that might reject an organ) or to treat rejection episodes.

Beyond these, IVIG is used for certain infections in specific scenarios: for example, severe COVID-19 patients received IVIG in some protocols; toxic shock syndrome from certain bacteria might be treated with IVIG to neutralize toxins; and as mentioned earlier, post-exposure prophylaxis immune globulins (like rabies or hepatitis B immune globulin) are essentially targeted forms of immunoglobulin therapy given IM or IV.

Why Intravenous?

The “IV” in IVIG is important. Delivering immune globulin by vein allows large doses of antibodies to be given and distributed quickly throughout the body. When given intravenously, the antibodies are immediately bioavailable in the bloodstream and tissues. Early forms of immunoglobulin therapy in the 1950s were given intramuscularly in small doses, but those were extremely painful and limited in how much antibody they could deliver. IV administration, which became feasible in the late 1970s after the development of IgG preparations that wouldn’t cause dangerous reactions, revolutionized immunoglobulin therapy. It meant that gram quantities of IgG (rather than milligram quantities) could be infused, which is what enabled treatment of immune deficiencies and high-dose autoimmune protocols.

The intravenous route also means a healthcare professional is present, which is important because immunoglobulin therapy can occasionally cause reactions. By being infused slowly under supervision, any adverse reactions can be managed. Common side effects during or after an IVIG infusion can include headache, mild fever, chills, muscle aches, or fatigue. These often result from the body’s immune response to the influx of proteins – essentially a transient inflammatory response. Slowing the infusion rate or splitting the dose over multiple days can alleviate some side effects. More rare but serious reactions include allergic reactions (anaphylaxis) especially in patients with IgA deficiency who may have anti-IgA antibodies (special IgA-depleted IVIG products are used in such cases), aseptic meningitis (severe headache and stiff neck, which is usually reversible after stopping IVIG), or blood clots in at-risk individuals (IVIG can increase blood viscosity). Careful screening and pre-medication can mitigate many risks. And remember, IVIG, being a blood-derived product, is put through rigorous testing and purification – the risk of viral transmission is extremely low; as of today, IVIG has a strong safety record in that regard.

Get Notified When Back in Stock